...vaccines business, including the 2012 acquisition of LigoCyte Pharmaceuticals Inc. and the 2013 acquisition of Inviragen Inc.... ...product, a norovirus VLP intranasal vaccine, is in Phase II testing to prevent norovirus gastroenteritis. Inviragen's...
...total of $118 million and produced ophthalmic surgery company LenSx Lasers Inc. and vaccine play Inviragen Inc.... ...Pharmaceutical Co. Ltd. (Tokyo:4502) paid $35 million plus up to $215 million in milestones for Inviragen...
...Inviragen for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's... ...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen... ...LLC was Inviragen's financial advisor, and Wilson Sonsini Goodrich & Rosati was Inviragen's legal advisor. Inviragen Inc....
...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire infectious disease company Inviragen Inc. (Fort Collins. Colo.) for $35... ...Colo.) for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's... ...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen...
...Cambodia and Myanmar a Japanese encephalitis (JE) vaccine based on Inviragen's cell-based JE production technology. Inviragen... ...vaccines and biologics. Inviragen declined to disclose additional details, while VABIOTECH could not be reached. Inviragen Inc....
...weeks apart induced neutralizing EV71 antibody responses in all subjects. The vaccine was well tolerated. Inviragen... ...it plans to evaluate the safety and efficacy of INV21 in children later this year. Inviragen Inc....
...vaccines business, including the 2012 acquisition of LigoCyte Pharmaceuticals Inc. and the 2013 acquisition of Inviragen Inc.... ...product, a norovirus VLP intranasal vaccine, is in Phase II testing to prevent norovirus gastroenteritis. Inviragen's...
...total of $118 million and produced ophthalmic surgery company LenSx Lasers Inc. and vaccine play Inviragen Inc.... ...Pharmaceutical Co. Ltd. (Tokyo:4502) paid $35 million plus up to $215 million in milestones for Inviragen...
...Inviragen for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's... ...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen... ...LLC was Inviragen's financial advisor, and Wilson Sonsini Goodrich & Rosati was Inviragen's legal advisor. Inviragen Inc....
...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire infectious disease company Inviragen Inc. (Fort Collins. Colo.) for $35... ...Colo.) for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's... ...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen...
...Cambodia and Myanmar a Japanese encephalitis (JE) vaccine based on Inviragen's cell-based JE production technology. Inviragen... ...vaccines and biologics. Inviragen declined to disclose additional details, while VABIOTECH could not be reached. Inviragen Inc....
...weeks apart induced neutralizing EV71 antibody responses in all subjects. The vaccine was well tolerated. Inviragen... ...it plans to evaluate the safety and efficacy of INV21 in children later this year. Inviragen Inc....
